Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on asymmetric catalytic hydrogenation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN106946823B reveals a novel catalytic route for high-purity (R)-jasmine lactone. This method reduces synthetic steps and improves optical purity for the flavor industry.
Discover a highly stereospecific process for paroxetine intermediates using chiral Ru-BINAP catalysts. Achieve superior purity and cost efficiency in API manufacturing.
Patent CN102417523A reveals novel nitrogen heterocyclic ligands enabling high-selectivity asymmetric hydrogenation of hindered ketones for cost-effective pharmaceutical manufacturing.
Patent CN102381988B reveals a high-efficiency route for Rivastigmine intermediates using Ru-catalyzed asymmetric hydrogenation, offering superior purity and cost reduction.
Patent CN109928995A introduces high-efficiency chiral ligands for carbonyl hydrogenation. Achieve superior enantioselectivity and scalable catalyst production for pharmaceutical manufacturing.
Patent CN103087105A discloses novel chiral phosphine ligands enabling high-efficiency asymmetric hydrogenation of beta-aryl enamides with exceptional enantioselectivity.
Novel patent CN119504764B offers high-yield Omarigliptin synthesis. Enhances supply chain reliability and reduces manufacturing costs for diabetes API intermediates.
Patented route for high-purity Rivastigmine intermediates using Ru-catalysis. Reduces cost and improves scalability for API manufacturing.
Patent CN109970795A details a novel iridium catalyst achieving 98% ee. Discover cost reduction in chiral ligand manufacturing and supply chain advantages.
Patent CN102951980A reveals a novel iridium-catalyzed method for producing chiral amines, offering significant cost reduction in agrochemical intermediate manufacturing and scalable supply chain solutions.
Patent CN112209967B reveals high-yield ligand synthesis. Offers cost reduction in pharmaceutical intermediates manufacturing and supply chain reliability.
Patent CN103415524B details stereoselective reduction for dorzolamide intermediates. Offers supply chain stability and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN110156645B details a streamlined 2-step asymmetric synthesis for florfenicol intermediates, drastically cutting waste and costs while ensuring high optical purity for veterinary pharmaceutical manufacturing supply chains.
Novel catalytic route for Tofacitinib reduces steps and improves purity. Ideal for pharmaceutical intermediate manufacturing cost reduction and supply chain reliability.
Patent CN114085219B details asymmetric hydrogenation for high-purity pharmaceutical intermediates. Offers cost reduction and scalable supply chain solutions for global buyers.
Patent CN113979983A reveals a high-efficiency Rh-catalyzed hydrogenation route for Fidarestat intermediates, offering superior enantioselectivity and cost reduction for pharmaceutical manufacturing.
Patent CN113603691A details a high-yield Rh-catalyzed process for L-5-methyltetrahydrofolic acid calcium, offering superior purity and cost efficiency for global supply chains.
Novel spirocyclic phosphoramidite ligands offer high stability and >99% ee for API synthesis, ensuring reliable supply and cost efficiency.
Patent CN109516943B reveals a novel catalytic route for lactam intermediates, offering significant cost reduction in API manufacturing and superior supply chain reliability.
Patent CN105218371A reveals a cost-effective Ru-catalyzed route for ethyl 3-hydroxy-4-(2,4,5-trifluorophenyl)butyrate, ensuring high purity and supply reliability.